(P = Proceedings, S = Supplement)
AARONS, L. see CALLIES, S.
ABDUL-MANAP, R. see MOGHADAMNIA, A.A.
ADITHAN, C., GERARD, N., VASU, S., ROSEMARY, J., SHASHINDRAN, C.H. & KRISHNAMOORTHY, R. Allele and genotype frequency of CYP2C19 in a Tamilian population: 331
AFFRIME, M. see GUPTA, S.K.
ALJAZAF, K., HALE, T.W., ILETT, K.F., HARTMANN, P.E., MITOULAS, L.R., KRISTENSEN, J.H. & HACKETT, L.P. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk: 18
ALLABI, A.C., GALA, J.-L., DESAGER, J.-P., HEUSTERSPREUTE, M. & HORSMANS, Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations: 653
ALLORGE, D., CHEVALIER, D., LO-GUIDICE, J.-M., CAUFFIEZ, C., SUARD, F., BAUMANN, P., EAP, C.B. & BROLY, F. Identification of a novel splice-site mutation in the CYP1A2 gene: 341
AL-SHURBAJI, A. see ANNAS, A.
ALVÁN, G. see ANNAS, A.
ANNAS, A., CARLSTRÖM, K., ALVÁN, G. & AL-SHURBAJI, A. The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment: 334
Announcement: 698
ANTMAN, E.M. see BRUNO, R.
ANTTILA, M., PENTTILÄ, J., HELMINEN, A., VUORILEHTO, L. & SCHEININ, H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects: 691
ARAI, H. see OHNUMA, T.
ARLET-SUAU, E. see ASTUDILLO, L.
ARONSON, J.K. Features of this month's Journal: 1, 141, 247, 347, 475
ARONSON, J.K. Nurse prescribers & reporters: 585
ASHWOOD, T. see ZINGMARK, P.-H.
ASTUDILLO, L., GUILLARD, O., SAILLER, L., RIGAL, F., COURET, B. & ARLET-SUAU, E. Lead poisoning by self-administration in an exposed worker: 695
AUTON, T.R. see DOWNHAM, M.R.
BABER, N. & PRITCHARD, D. Dose estimation for children: 489
BABER, N. see MUCKLOW, J.
BACKMAN, J.T. see NIEMI, M.
BAILLE, P. see BRUNO, R.
BALRAM, C., SHARMA, A., SIVATHASAN, C. & LEE, E.J.D. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates: 78
BARNES, T.R.E. see FLANAGAN, R.J.
BATEMAN, D.N. see CAMIDGE, D.R.
BATEMAN, D.N. see LANGFORD, N.J.
BAUMANN, P. see ALLORGE, D.
BECKER, R. see BRUNO, R.
BEIJNEN, J.H. see CALLIES, S.
BELLDINA, E.B., HUANG, M.Y., SCHNEIDER, J.A., BRUNDAGE, R.C. & TRACY, T.S. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients: 520
BELLE, D. see GUPTA, S.K.
BELZ, G.G. Angiotensin II dose–effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology: 3
BENNETT, T. see DOWNHAM, M.R.
BENÖHR, P. see FREUDENTHALER, S.
BERGSTROM, R.F. see SATHIRAKUL, K.
BERTILSSON, L. see HÄRTTER, S.
BERTILSSON, L. see HELLMAN, K.
BERTILSSON, L. see HERRLIN, K.
BIDSTRUP, T.B., BJØRNSDOTTIR, I., SIDELMANN, U.G., THOMSEN, M.S. & HANSEN, K.T. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide: 305
BITZER, J. see PFRUNDER, A.
BJØRNSDOTTIR, I. see BIDSTRUP, T.B.
BJARNASON, I. see SMALE, S.
BOOS, J. see HEMPEL, G.
BOURIN, M. see DAILLY, E.
BOYLE, J. see WILSON, Z.E.
BRADBURY, B.D. see KAYE, J.A.
BRADY, A. see PATTERSON, D.
BREDDIN, H.K. see GRAFF, J.
BRIEN, S., LEWITH, G. & BRYANT, T. Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C: 562
BROADHURST, C., WILSON, K.C.M., KINIRONS, M.T., WAGG, A. & DHESI, J.K. Clinical pharmacology of old age syndromes: 261
BROLY, F. see ALLORGE, D.
BRUNDAGE, R.C. see BELLDINA, E.B.
BRUNO, R., BAILLE, P., RETOUT, S., VIVIER, N., VEYRAT-FOLLET, C., SANDERINK, G.-J., BECKER, R. & ANTMAN, E.M. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction: 407
BRYANT, T. see BRIEN, S.
BURGESS, M. see CALLIES, S.
BURHENNE, J. see RENGELSHAUSEN, J.
BURN, J.L. see WILSON, Z.E.
CAI, W.-M. see YAN, F.-X.
CALLIES, S., DE ALWIS, D.P., HARRIS, A., VASEY, P., BEIJNEN, J.H., SCHELLENS, J.H., BURGESS, M. & AARONS, L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979): 46
CAMIDGE, D.R., WOOD, R.J. & BATEMAN, D.N. The epidemiology of self-poisoning in the UK: 613
CARBONARA, O. see SASSO, F.C.
CARLSTRÖM, K. see ANNAS, A.
CARTY, E. & RAMPTON, D.S. Evaluation of new therapies for inflammatory bowel disease: 351
CAUFFIEZ, C. see ALLORGE, D.
CAZALI, N., TRAN, A., TRELUYER, J.M., REY, E., D'ATHIS, P., VINCENT, J. & PONS, G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human: 526
CHAN, C. see SATHIRAKUL, K.
CHAN, T.M. see KUMANA, C.R.
CHEVALIER, D. see ALLORGE, D.
CHOWDRY, J. see SHIRAN, M.R.
CHRYSTYN, H. see TOMLINSON, H.S.
COCKBURN, W.J. see LEE, D.K.C.
COCKBURN, W.J.R. see CURRIE, G.P.
COHEN, E. see SHARABI, A.
COPPOLA, L. see SASSO, F.C.
CORLETT, S.A. see TOMLINSON, H.S.
COURET, B. see ASTUDILLO, L.
CREUTZIG, U. see HEMPEL, G.
CUMMINGS, M.H. see FAYERS, K.E.
CURRIE, G.P. see LEE, D.K.C.
CURRIE, G.P., LIMA, J.J., SYLVESTER, J.E., LEE, D.K.C., COCKBURN, W.J.R. & LIPWORTH, B.J. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma: 422
CURRIE, G.P., STENBACK, S. & LIPWORTH, B.J. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma: 11
D'ATHIS, P. see CAZALI, N.
DAHLEM, P. see DUIJVESTIJN, Y.C.M.
DAILLY, E., PANNIER, M., JOLLIET, P. & BOURIN, M. Population pharmacokinetics of ceftazidime in burn patients: 629
DARIMONT, J. see SKARKE, C.
DAVIES, D.P. see SRI RANGANATHAN, S.
DAWIDOWICZ, A.L., KALITYNSKI, R. & FIJALKOWSKA, A. Free and bound propofol concentrations in human cerebrospinal fluid: 545
DAWSON, A.H. see ISBISTER, G.K.
DAY, R.O. see SASONGKO, L.
DE ALWIS, D.P. see CALLIES, S.
DE GLANVILLE, H. & FERNER, R. David Margerison Davies, 1923–2002: 139
DE GRAAF, L. & DIEMONT, W.L. Chest pain during use of bupropion as an aid in smoking cessation: 451
DELANEY, C. see LIAO, W.-C.
DESAGER, J.-P. see ALLABI, A.C.
DHESI, J.K. see BROADHURST, C.
DICPINIGAITIS, P.V. & GAYLE, Y.E. Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function: 501
DIEMONT, W.L. see DE GRAAF, L.
DOLOVICH, M.B. see LABIRIS, N.R.
DOMSCHKE, W. see POHLE, T.
DOWNHAM, M.R., AUTON, T.R., ROSUL, A., SHARP, H.L., SJÖSTRÖM, L., RUSHTON, A., RICHARDS, J.P., MANT, T.G.K., GARDINER, S.M., BENNETT, T. & GLOVER, J.F. Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man: 505
DREWE, J. see PFRUNDER, A.
DUFFULL, S.B. see GREEN, B.
DUFFULL, S.B. see SHUM, B.
DUIJVESTIJN, Y.C.M., KALMEIJER, M.D., PASSIER, A.L.M., DAHLEM, P. & SMIERS, F. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine: 581
EAP, C.B. see ALLORGE, D.
EDWARDS, G. see OGUTU, B.R.
EDWARDS, G. see THOMSON, A.H.
EICHLERL, H.-G. see SYCHA, T.
EKBLOM, M. see ZINGMARK, P.-H.
EKINS-DAUKES, S., MCLAY, J.S., TAYLOR, M.W., SIMPSON, C.R. & HELMS, P.J. Antibiotic prescribing for children. Too much and too little? Retrospective observational study in primary care: 92
EL-ERAKY, H. & THOMAS, S.H.L. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine: 198
ELLIS, S.W. see SHIRAN, M.R.
ELLIS, S.W. see WILSON, Z.E.
ENGLISH, M. see THOMSON, A.H.
Errata: 463, 584
FANTI, P. see YAN, F.-X.
FAYERS, K.E., CUMMINGS, M.H., SHAW, K.M. & LAIGHT, D.W. Nitrate tolerance and the links with endothelial dysfunction and oxidative stress: 620
FERNER, R. see DE GLANVILLE, H.
FERREIRA, I. see LIAO, W.-C.
FERRON, G.M., PATAT, A., PARKS, V., ROLAN, P. & TROY, S.M. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects: 39
FIJALKOWSKA, A. see DAWIDOWICZ, A.L.
FLANAGAN, R.J. & JONES, A.L. Antidotes: Principles and Clinical Applications: 458
FLANAGAN, R.J. The Forensic Pharmacology of Drugs of Abuse: 345
FLANAGAN, R.J., YUSUFI, B. & BARNES, T.R.E. Comparability of whole-blood and plasma clozapine and norclozapine concentrations: 135
FORD, N. see LIAO, W.-C.
FREDRIKSON, S. see HELLMAN, K.
FREUDENTHALER, S., BENÖHR, P., GRENZ, A., SELZER, T., SCHMIDT, T., MÖRIKE, K., OSSWALD, H. & GLEITER, C.H. Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?: 378
FROSSARD, N. see PUROHIT, A.
FUJIMURA, A. see SUGIMOTO, K.-I.
GALA, J.-L. see ALLABI, A.C.
GARDINER, S.M. see DOWNHAM, M.R.
GARTY, M. see SHARABI, A.
GAYLE, Y.E. see DICPINIGAITIS, P.V.
GEISSLINGER, G. see SKARKE, C.
GERARD, N. see ADITHAN, C.
GERBER, S. see PFRUNDER, A.
GLEITER, C.H. see FREUDENTHALER, S.
GLOVER, J.F. see DOWNHAM, M.R.
GLUE, P. see GUPTA, S.K.
GÖGGELMANN, C. see RENGELSHAUSEN, J.
GODDARD, A.F. & LOGAN, R.P.H. Diagnostic methods for Helicobacter pylori detection and eradication: 273
GOOD, A.M. see LANGFORD, N.J.
GRAFF, J., KLINKHARDT, U., WESTRUP, D., KIRCHMAIER, C.M., BREDDIN, H.K. & HARDER, S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans: 321
GREEN, B. & DUFFULL, S.B. Development of a dosing strategy for enoxaparin in obese patients: 96
GREENBLATT, D.J. see OLUBODUN, J.O.
GREGOOR, P.J.H.S. see HESSELINK, D.A.
GRENZ, A. see FREUDENTHALER, S.
GUILLARD, O. see ASTUDILLO, L.
GUPTA, S.K., GLUE, P., JACOBS, S., BELLE, D. & AFFRIME, M. Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects: 131
GUSTAFSSON, L.L. see HELLMAN, K.
GUSTAFSSON, L.L. see HERRLIN, K.
GUSTORFF, B. see SYCHA, T.
HÄRTTER, S., NORDMARK, A., ROSE, D.-M., BERTILSSON, L., TYBRING, G. & LAINE, K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity: 679
HAAS, C.S. see RENDERS, L.
HACKETT, L.P. see ALJAZAF, K.
HACKETT, L.P. see ISBISTER, G.K.
HAEFELI, W.E. see RENGELSHAUSEN, J.
HALE, T.W. see ALJAZAF, K.
HANSEN, K.T. see BIDSTRUP, T.B.
HARA, K. see IWASA, T.
HARDER, S. see GRAFF, J.
HARDER, S. see TOENNES, S.W.
HARMATZ, J.S. see OLUBODUN, J.O.
HARRIS, A. see CALLIES, S.
HARTMANN, P.E. see ALJAZAF, K.
HASCHKE, M. see PFRUNDER, A.
HAWKEY, C.J. see JAMES, M.W.
HAYCOX, A. see KUMANA, C.R.
HELLMAN, K., ROOS, E., ÖSTERLUND, A., WAHLBERG, A., GUSTAFSSON, L.L., BERTILSSON, L. & FREDRIKSON, S. Interferon-β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity: 337
HELMINEN, A. see ANTTILA, M.
HELMS, P.J. see EKINS-DAUKES, S.
HEMPEL, G., REINHARDT, D., CREUTZIG, U. & BOOS, J. Population pharmacokinetics of liposomal daunorubicin in children: 370
HERRLIN, K., YASUI-FURUKORI, N., TYBRING, G., WIDÉN, J., GUSTAFSSON, L.L. & BERTILSSON, L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes: 415
HESSE, L.M. see OLUBODUN, J.O.
HESSELINK, D.A., NGYUEN, H., WABBIJN, M., GREGOOR, P.J.H.S., STEYERBERG, E.W., VAN RIEMSDIJK, I.C., WEIMAR, W. & VAN GELDER, T. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids: 327
HEUSTERSPREUTE, M. see ALLABI, A.C.
HORNUNG, C. see YAN, F.-X.
HORSMANS, Y. see ALLABI, A.C.
HOUGHTON, J.E. see SRI RANGANATHAN, S.
HUANG, M.Y. see BELLDINA, E.B.
IHNEN, M.A. see YAN, F.-X.
ILETT, K.F. see ALJAZAF, K.
Indices for Volume 56: 699
IQBAL, M.Z. see SHIRAN, M.R.
ISBISTER, G.K., HACKETT, L.P., DAWSON, A.H., WHYTE, I.M. & SMITH, A.J. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity: 441
ISHIBASHI, T., YANO, Y. & OGUMA, T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients: 205
ISHIZAKI, T. see IWASA, T.
ITOH, S. see NAKAGAWA, T.
IWASA, T., SANO, H., SUGIURA, A., UCHIYAMA, N., HARA, K., OKOCHI, H., NAKAGAWA, K., YASUMORI, T. & ISHIZAKI, T. An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug: 537
JACKSON, C.M. see LEE, D.K.C.
JACKSON, C.M. see SIMS, E.J.
JACKSON, S.H.D. see MOORE, A.
JACOBS, S. see GUPTA, S.K.
JAMES, M.W. & HAWKEY, C.J. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract: 146
JEMAL, M. see LIAO, W.-C.
JICK, H. see KAYE, J.A.
JICK, S.S. see YANG, C.-C.
JOLLIET, P. see DAILLY, E.
JONES, A.L. see FLANAGAN, R.J.
JONSSON, E.N. see ZINGMARK, P.-H.
JURONEN, E. see YAN, F.-X.
KALITYNSKI, R. see DAWIDOWICZ, A.L.
KALMEIJER, M.D. see DUIJVESTIJN, Y.C.M.
KAMALI, F. Introduction to Drug Metabolism (Third Edition): 345
KARLSSON, M.O. see KERBUSCH, T.
KARLSSON, M.O. see ZINGMARK, P.-H.
KAUERT, G.F. see TOENNES, S.W.
KAYE, J.A., BRADBURY, B.D. & JICK, H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study: 569
KENDALL, M.J. Drugs Handbook 2003: 579
KERBUSCH, T., WÄHLBY, U., MILLIGAN, P.A. & KARLSSON, M.O. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability: 639
KINIRONS, M.T. see BROADHURST, C.
KIRCHMAIER, C.M. see GRAFF, J.
KISHINO, S. see NAKAGAWA, T.
KLINKHARDT, U. see GRAFF, J.
KNOWLES, S.R. see PHILLIPS, E.J.
KOKWARO, G.O. see OGUTU, B.R.
KOKWARO, G.O. see THOMSON, A.H.
KOKWARO, G.O., OGUTU, B.R., MUCHOHI, S.N., OTIENO, G.O. & NEWTON, C.R.J.C. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions: 453
KOU, M. see KUMANA, C.R.
KRISHNAMOORTHY, R. see ADITHAN, C.
KRISTENSEN, J.H. see ALJAZAF, K.
KUMANA, C.R., TONG, M.K.L., LI, C.-S., LAUDER, I.J., LEE, J.S.K., KOU, M., WALLEY, T., HAYCOX, A. & CHAN, T.M. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin: 670
KUNZENDORF, U. see RENDERS, L.
LABIRIS, N.R. & DOLOVICH, M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications: 588
LABIRIS, N.R. & DOLOVICH, M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications: 600
LAGUNDOYE, O. see SHIRAN, M.R.
LAIGHT, D.W. see FAYERS, K.E.
LAINE, K. see HÄRTTER, S.
LAINE, K. see PALOVAARA, S.
LAING, W.J. see LANGFORD, N.J.
LANGFORD, N.J., GOOD, A.M., LAING, W.J. & BATEMAN, D.N. Quinine intoxications reported to the Scottish Poisons Information Bureau 1997–2002: a continuing problem: 576
LANGUB, M.C. see YAN, F.-X.
LAUDER, I.J. see KUMANA, C.R.
LEE, D.K.C. see CURRIE, G.P.
LEE, D.K.C., JACKSON, C.M., CURRIE, G.P., COCKBURN, W.J. & LIPWORTH, B.J. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma: 494
LEE, E.J.D. see BALRAM, C.
LEE, J.S.K. see KUMANA, C.R.
LEHR, S. see SYCHA, T.
LENNARD, M.S. see SHIRAN, M.R.
LEWITH, G. see BRIEN, S.
LI, C.-S. see KUMANA, C.R.
LIAO, W.-C., VESTERQVIST, O., DELANEY, C., JEMAL, M., FERREIRA, I., FORD, N., SWANSON, B. & UDERMAN, H. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects: 395
LIEBELT, J. see RENDERS, L.
LIMA, J.J. see CURRIE, G.P.
LIPWORTH, B.J. see CURRIE, G.P.
LIPWORTH, B.J. see LEE, D.K.C.
LIPWORTH, B.J. see SIMS, E.J.
LÖTSCH, J. see SKARKE, C.
LOGAN, R.P.H. see GODDARD, A.F.
LO-GUIDICE, J.-M. see ALLORGE, D.
LUDWIG, J. see RENGELSHAUSEN, J.
LYDEN, P. see ZINGMARK, P.-H.
LYONS, D. see MOORE, A.
MA, B. see PRUEKSARITANONT, T.
MACDONALD, T. see PATTERSON, D.
MAMDANI, M.M. see RAY, J.G.
MANGONI, A.A. see MOORE, A.
MANT, T.G.K. see DOWNHAM, M.R.
MATSUBARA, Y. see OHNUMA, T.
MAXWELL, S. see MUCKLOW, J.
MCINNES, G. see PATTERSON, D.
MCLACHLAN, A.J. see SASONGKO, L.
MCLAY, J.S. see EKINS-DAUKES, S.
MELAC, M. see PUROHIT, A.
MICCO, P.D. see SASSO, F.C.
MIKUS, G. see RENGELSHAUSEN, J.
MILLIGAN, P.A. see KERBUSCH, T.
MITOULAS, L.R. see ALJAZAF, K.
MIYAZAKI, K. see NAKAGAWA, T.
MÖRIKE, K. see FREUDENTHALER, S.
MOGHADAMNIA, A.A., ROSTAMI-HODJEGAN, A., ABDUL-MANAP, R., WRIGHT, C.E., MORICE, A.H. & TUCKER, G.T. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition: 57
MOHAMMED, S. see THOMSON, A.H.
MOORE, A., MANGONI, A.A., LYONS, D. & JACKSON, S.H.D. The cardiovascular system in the ageing patient: 254
MORICE, A.H. see MOGHADAMNIA, A.A.
MUCHOHI, S.N. see KOKWARO, G.O.
MUCHOHI, S.N. see OGUTU, B.R.
MUCHOHI, S.N. see THOMSON, A.H.
MUCKLOW, J., BABER, N., MAXWELL, S. & PIRMOHAMED, M. The BPS web site for Continuing Professional Development in Clinical Pharmacology and Therapeutics: 349
NAKAGAWA, K. see IWASA, T.
NAKAGAWA, T., KISHINO, S., ITOH, S., SUGAWARA, M. & MIYAZAKI, K. Differential binding of disopyramide and warfarin enantiomers to human α1-acid glycoprotein variants: 664
NEUVONEN, M. see NIEMI, M.
NEUVONEN, P.J. see NIEMI, M.
NEWTON, C.R.J.C. see KOKWARO, G.O.
NEWTON, C.R.J.C. see OGUTU, B.R.
NGYUEN, H. see HESSELINK, D.A.
NIEMI, M., BACKMAN, J.T., NEUVONEN, M. & NEUVONEN, P.J. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects: 427
NIESS, C. see TOENNES, S.W.
NIGLIO, A. see SASSO, F.C.
NORDMARK, A. see HÄRTTER, S.
ÖSTERLUND, A. see HELLMAN, K.
OBERBARNSCHEIDT, M. see RENDERS, L.
OCHS, H.R. see OLUBODUN, J.O.
ODERGREN, T. see ZINGMARK, P.-H.
OGUMA, T. see ISHIBASHI, T.
OGUTU, B.R. see KOKWARO, G.O.
OGUTU, B.R., NEWTON, C.R.J.C., MUCHOHI, S.N., OTIENO, G.O., EDWARDS, G., WATKINS, W.M. & KOKWARO, G.O. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus: 112
OHNUMA, T., SHIBATA, N., MATSUBARA, Y. & ARAI, H. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6: 315
OKOCHI, H. see IWASA, T.
OLUBODUN, J.O., OCHS, H.R., VON MOLTKE, L.L., ROUBENOFF, R., HESSE, L.M., HARMATZ, J.S., SHADER, R.I. & GREENBLATT, D.J. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men: 297
OSSWALD, H. see FREUDENTHALER, S.
OTIENO, G.O. see KOKWARO, G.O.
OTIENO, G.O. see OGUTU, B.R.
PALOVAARA, S., TYBRING, G. & LAINE, K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects: 232
PANNIER, M. see DAILLY, E.
PARKS, V. see FERRON, G.M.
PASSIER, A.L.M. see DUIJVESTIJN, Y.C.M.
PATAT, A. see FERRON, G.M.
PATTERSON, D., WEBSTER, J., MCINNES, G., BRADY, A. & MACDONALD, T. The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension: 513
PAULI, G. see PUROHIT, A.
PENTTILÄ, J. see ANTTILA, M.
PFRUNDER, A., SCHIESSER, M., GERBER, S., HASCHKE, M., BITZER, J. & DREWE, J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial: 683
PHILLIPS, E.J., KNOWLES, S.R. & SHEAR, N.H. Serum sickness-like reaction associated with clopidogrel: 583
PIRMOHAMED, M. see MUCKLOW, J.
POHLE, T. & DOMSCHKE, W. Gastric function measurements in drug development: 156
PONS, G. see CAZALI, N.
PRICE, A.B. Pathology of drug-associated gastrointestinal disease: 477
PRITCHARD, D. see BABER, N.
Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 10 October 2003: 465
Proceedings of the London Hypertension Society 20 May 2003: 240
PRUEKSARITANONT, T., MA, B. & YU, N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6: 120
PUROHIT, A., MELAC, M., PAULI, G. & FROSSARD, N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin: 388
RAMPTON, D.S. see CARTY, E.
RAY, J.G. & MAMDANI, M.M. Statins and the risk of idiopathic venous thromboembolism: 460
RAYENS, M.K. see YAN, F.-X.
REINHARDT, D. see HEMPEL, G.
RENDERS, L., HAAS, C.S., LIEBELT, J., OBERBARNSCHEIDT, M., SCHÖCKLMANN, H.O. & KUNZENDORF, U. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients: 214
RENGELSHAUSEN, J., GÖGGELMANN, C., BURHENNE, J., RIEDEL, K.-D., LUDWIG, J., WEISS, J., MIKUS, G., WALTER-SACK, I. & HAEFELI, W.E. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction: 32
RETOUT, S. see BRUNO, R.
REY, E. see CAZALI, N.
RICHARDS, J.P. see DOWNHAM, M.R.
RIEDEL, K.-D. see RENGELSHAUSEN, J.
RIGAL, F. see ASTUDILLO, L.
ROLAN, P. see FERRON, G.M.
ROOS, E. see HELLMAN, K.
ROSE, D.-M. see HÄRTTER, S.
ROSEMARY, J. see ADITHAN, C.
ROSTAMI-HODJEGAN, A. see MOGHADAMNIA, A.A.
ROSTAMI-HODJEGAN, A. see SHIRAN, M.R.
ROSTAMI-HODJEGAN, A. see WILSON, Z.E.
ROSUL, A. see DOWNHAM, M.R.
ROUBENOFF, R. see OLUBODUN, J.O.
ROUTLEDGE, P.A. see SRI RANGANATHAN, S.
RUSHTON, A. see DOWNHAM, M.R.
SAILLER, L. see ASTUDILLO, L.
SANDERINK, G.-J. see BRUNO, R.
SANO, H. see IWASA, T.
SASONGKO, L., WILLIAMS, K.M., DAY, R.O. & MCLACHLAN, A.J. Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques: 551
SASSO, F.C., CARBONARA, O., MICCO, P.D., COPPOLA, L., TORELLA, R. & NIGLIO, A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy: 238
SATHIRAKUL, K., CHAN, C., TENG, L., BERGSTROM, R.F., YEO, K.P. & WISE, S.D. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects: 184
SCHACTER, M. Principles of Clinical Pharmacology: 579
SCHEININ, H. see ANTTILA, M.
SCHELLENS, J.H. see CALLIES, S.
SCHIESSER, M. see PFRUNDER, A.
SCHMETTERER, L. see SYCHA, T.
SCHMIDT, H. see SKARKE, C.
SCHMIDT, T. see FREUDENTHALER, S.
SCHMITZ, G. & TORZEWSKI, M. HMG-Co reductase inhibitors: 458
SCHNEIDER, J.A. see BELLDINA, E.B.
SCHÖCKLMANN, H.O. see RENDERS, L.
SCHRAMM, M. see TOENNES, S.W.
SEIVEWRIGHT, N. see SHIRAN, M.R.
SELZER, T. see FREUDENTHALER, S.
SHADER, R.I. see OLUBODUN, J.O.
SHARABI, A., COHEN, E., SULKES, J. & GARTY, M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route: 635
SHARMA, A. see BALRAM, C.
SHARP, H.L. see DOWNHAM, M.R.
SHASHINDRAN, C.H. see ADITHAN, C.
SHAW, K.M. see FAYERS, K.E.
SHEAR, N.H. see PHILLIPS, E.J.
SHENFIELD, G. Clinical Pharmacology: 694
SHIBATA, N. see OHNUMA, T.
SHIRAN, M.R., CHOWDRY, J., ROSTAMI-HODJEGAN, A., ELLIS, S.W., LENNARD, M.S., IQBAL, M.Z., LAGUNDOYE, O., SEIVEWRIGHT, N. & TUCKER, G.T. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment: 220
SHUM, B., DUFFULL, S.B., TAYLOR, P.J. & TETT, S.E. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil: 188
SIDELMANN, U.G. see BIDSTRUP, T.B.
SIMPSON, C.R. see EKINS-DAUKES, S.
SIMS, E.J., JACKSON, C.M. & LIPWORTH, B.J. Add-on therapy with montelukast or formoterol in patients with the glycine-16 β2-receptor genotype: 104
SIVATHASAN, C. see BALRAM, C.
SJÖSTRÖM, L. see DOWNHAM, M.R.
SKARKE, C., SCHMIDT, H., GEISSLINGER, G., DARIMONT, J. & LÖTSCH, J. Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome: 228
SMALE, S. & BJARNASON, I. Determining small bowel integrity following drug treatment: 284
SMIERS, F. see DUIJVESTIJN, Y.C.M.
SMITH, A.J. see ISBISTER, G.K.
SRI RANGANATHAN, S., HOUGHTON, J.E., DAVIES, D.P. & ROUTLEDGE, P.A. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme: 658
STENBACK, S. see CURRIE, G.P.
STEYERBERG, E.W. see HESSELINK, D.A.
SUARD, F. see ALLORGE, D.
SUGAWARA, M. see NAKAGAWA, T.
SUGIMOTO, K.-I. & FUJIMURA, A. Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II: 696
SUGIURA, A. see IWASA, T.
SULKES, J. see SHARABI, A.
SWANSON, B. see LIAO, W.-C.
SWIFT, C.G. The clinical pharmacology of ageing: 249
SYCHA, T., GUSTORFF, B., LEHR, S., TANEW, A., EICHLERL, H.-G. & SCHMETTERER, L. A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects: 165
SYLVESTER, J.E. see CURRIE, G.P.
TALLEY, N.J. Evaluation of drug treatment in irritable bowel syndrome: 362
TANEW, A. see SYCHA, T.
TAYLOR, M.W. see EKINS-DAUKES, S.
TAYLOR, P.J. see SHUM, B.
TENG, L. see SATHIRAKUL, K.
TESTA, M.A. see YANG, C.-C.
TETT, S.E. see SHUM, B.
THOMAS, S.H.L. see EL-ERAKY, H.
THOMSEN, M.S. see BIDSTRUP, T.B.
THOMSON, A.H., KOKWARO, G.O., MUCHOHI, S.N., ENGLISH, M., MOHAMMED, S. & EDWARDS, G. Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya: 25
TOENNES, S.W., HARDER, S., SCHRAMM, M., NIESS, C. & KAUERT, G.F. Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves: 125
TOMLINSON, H.S., CORLETT, S.A. & CHRYSTYN, H. Dose–response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation: 225
TONG, M.K.L. see KUMANA, C.R.
TOOLEY, A. see WILSON, Z.E.
TORELLA, R. see SASSO, F.C.
TORZEWSKI, M. see SCHMITZ, G.
TRACY, T.S. see BELLDINA, E.B.
TRAN, A. see CAZALI, N.
TRELUYER, J.M. see CAZALI, N.
TROY, S.M. see FERRON, G.M.
TUCKER, G.T. see MOGHADAMNIA, A.A.
TUCKER, G.T. see SHIRAN, M.R.
TUCKER, G.T. see WILSON, Z.E.
TYBRING, G. see HÄRTTER, S.
TYBRING, G. see HERRLIN, K.
TYBRING, G. see PALOVAARA, S.
UCHIYAMA, N. see IWASA, T.
UDERMAN, H. see LIAO, W.-C.
VAN GELDER, T. see HESSELINK, D.A.
VAN RIEMSDIJK, I.C. see HESSELINK, D.A.
VASEY, P. see CALLIES, S.
VASU, S. see ADITHAN, C.
VESTERQVIST, O. see LIAO, W.-C.
VEYRAT-FOLLET, C. see BRUNO, R.
VINCENT, J. see CAZALI, N.
VIVIER, N. see BRUNO, R.
VON MOLTKE, L.L. see OLUBODUN, J.O.
VOZˇEH, S. Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?: 292
VUORILEHTO, L. see ANTTILA, M.
WÄHLBY, U. see KERBUSCH, T.
WABBIJN, M. see HESSELINK, D.A.
WAGG, A. see BROADHURST, C.
WAHLBERG, A. see HELLMAN, K.
WALKER, M.M. & WHITTLE, B.J.R. British Journal of Clinical Pharmacology review series Clinical research methods in gastroenterology: 143
WALKER, M.M. Biopsy assessment of drug efficacy in the gastrointestinal tract: 483
WALLEY, T. see KUMANA, C.R.
WALTER-SACK, I. see RENGELSHAUSEN, J.
WATKINS, W.M. see OGUTU, B.R.
WEBSTER, J. see PATTERSON, D.
WEDLUND, P.J. see YAN, F.-X.
WEIMAR, W. see HESSELINK, D.A.
WEISS, J. see RENGELSHAUSEN, J.
WESTRUP, D. see GRAFF, J.
WHITTLE, B.J.R. see WALKER, M.M.
WHYTE, I.M. see ISBISTER, G.K.
WIDÉN, J. see HERRLIN, K.
WILLIAMS, K.M. see SASONGKO, L.
WILSON, K.C.M. see BROADHURST, C.
WILSON, Z.E., ROSTAMI-HODJEGAN, A., BURN, J.L., TOOLEY, A., BOYLE, J., ELLIS, S.W. & TUCKER, G.T. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver: 433
WISE, S.D. see SATHIRAKUL, K.
WOOD, R.J. see CAMIDGE, D.R.
WRIGHT, C.E. see MOGHADAMNIA, A.A.
YAN, F.-X., LANGUB, M.C., IHNEN, M.A., HORNUNG, C., JURONEN, E., RAYENS, M.K., CAI, W.-M., WEDLUND, P.J. & FANTI, P. CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy: 68
YANG, C.-C. & JICK, S.S. Author's response to letter from Ray et al.: 461
YANG, C.-C., JICK, S.S. & TESTA, M.A. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics: 84
YANO, Y. see ISHIBASHI, T.
YASUI-FURUKORI, N. see HERRLIN, K.
YASUMORI, T. see IWASA, T.
YEO, K.P. see SATHIRAKUL, K.
YU, N. see PRUEKSARITANONT, T.
YUSUFI, B. see FLANAGAN, R.J.
ZINGMARK, P.-H., EKBLOM, M., ODERGREN, T., ASHWOOD, T., LYDEN, P., KARLSSON, M.O. & JONSSON, E.N. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients: 173